Clinical Outcomes Based on the Attainment of Low-Density Lipoprotein Cholesterol Targets in Patients with Acute Coronary Syndrome in Real-World Practice
Table 1
Baseline characteristics and clinical outcomes in the patients with and without decreasing LDL-C level ≥50%.
Decreasing ≥ 50%
Decreasing < 50%
value
Number
3367
11153
General demographics
Age (years)
61 (12.7)
65 (12.9)
<0.001
Male sex (%)
2611 (77.55)
8124 (72.84)
<0.001
BMI (kg/m2)
25.77 (3.89)
25.52 (4.22)
0.006
Comorbidities
Smoking (%)
708 (21.03)
1947 (17.46)
<0.001
Hypertension (%)
1996 (59.28)
6891 (61.79)
0.009
Diabetes mellitus (%)
1492 (44.31)
4592 (41.17)
0.001
PAOD (%)
11 (0.33)
75 (0.67)
0.022
COPD (%)
88 (2.61)
455 (4.08)
<0.001
ESRD (%)
222 (6.59)
869 (7.79)
0.021
Liver cirrhosis (%)
22 (0.65)
138 (1.24)
0.004
Prior GI bleeding (%)
157 (4.66)
834 (7.48)
<0.001
Prior stroke (%)
151 (4.48)
598 (5.36)
0.044
Lipid lower agents (%)
High-intensity statin (%)
2737 (81.29)
5904 (52.94)
<0.001
Ezetimibe (%)
535 (15.89)
1415 (12.69)
<0.001
LDL-C level (mg/dl)
Baseline level (mg/dL)
140.80 ± 39.26
101.60 ± 36.20
<0.001
The lowest level (mg/dL)
55.61 ± 17.47
85.78 ± 29.57
<0.001
Decreasing percentage (%)
60.22 ± 7.70
8.12 ± 47.05
<0.001
Clinical outcomes
1-year
CV mortality (%)
60 (1.78)
262 (2.35)
0.050
All-cause mortality (%)
147 (4.37)
689 (6.18)
<0.001
3-year
CV mortality (%)
145 (4.31)
618 (5.54)
0.005
All-cause mortality (%)
401 (11.91)
1831 (16.42)
<0.001
F/U period (years)
2.6 (0.7)
2.5 (0.8)
0.007
Data are expressed as the mean (standard deviation) or as a number (percentage). Abbreviation: LDL-C, low density lipoprotein-cholesterol; BMI, body mass index; PAOD, peripheral arterial occlusive disease; COPD, chronic obstructive pulmonary disease; ESRD, end stage renal disease; GI, gastrointestinal; CV, cardiovascular; F/U, follow-up.
